NeuroOne Medical Technologies Corporation announced that it has appointed medtech executive Christopher R. Volker as Chief Operating Officer. Mr. Volker joins NeuroOne from Abbott Laboratories which.
The AZALEA-TIMI 71 randomized trial evaluated the safety and tolerability of 2 blinded doses of the novel factor XI inhibitor abelacimab compared with open-label rivaroxaban.
NeuroOne® Appoints Medtech Executive Christopher R Volker as Chief Operating Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
TIMI Study: Novel Anti-Clot Drug Cuts Bleeding in A-Fib Patients miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
STEMI patients taking the traditional Chinese medicine Tongxinluo, containing extracts of multiple plants and insects, had fewer MIs, strokes, and other events in the randomized CTS-AMI trial.